REGENLAB
RegenLab, a pioneering biotechnology company specializing in the research, development, and manufacturing of patented cell and tissue engineering medical devices, has been honored with the “Innovation Champion Award” by the European Investment Bank (EIB) at the European Convention Center in Luxembourg.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611846846/en/
RegenLab France receives prestigious EU-EIB Innovation Champion Award. Antoine Turzi, CEO and Founder of RegenLab, pictured between two officials of the European Investment Bank. (Photo: Business Wire)
This prestigious award recognizes RegenLab France’s commitment to “reshoring” by establishing a state-of-the-art biotechnology factory in Paris-Saclay and its innovation, the REGENMATRIX® PRP-HA. This next-generation product combines Platelet-Rich Plasma (PRP) with cross-linked Hyaluronic Acid (HA) in a single tube, designed specifically to address the needs of patients with advanced grade III-IV knee osteoarthritis. Currently, a clinical study is underway in 16 university hospitals across France to demonstrate the effectiveness and safety of this groundbreaking treatment.
“We are honored and delighted to receive this award from the European Investment Bank,” said Mr. Antoine Turzi, Founder & CEO of RegenLab France. “This recognition celebrates the successful completion of our French factory and our ongoing R&D efforts. Our goal is to innovate in cell therapies and enhance the well-being of patients, while supporting industry reshoring in France.”
RegenLab’s achievement not only highlights its dedication to advancing medical science but also underscores the pivotal role of the EIB in promoting innovation, its sustainable growth across Europe and its competitiveness worldwide.
Based in Paris Saclay, RegenLab France is a company specialized in the R&D and manufacturing of tissue engineering medical devices supported by 100 patents. The Company’s solutions are commercialized in more than 90 countries. The core technology of the Company is manufacturing of medical devices for autologous platelet-rich plasma (PRP) & Tissue Engineering, consisting in reinjecting the patient’s own cells and platelets into tissue lesions in order to stimulate tissue healing. The RegenKit, CellularMatrix… brands, have been CE marked EU-MDR 2017/745 and approved by US-FDA, CFDA & worldwide regulatory agencies; they are routinely used for the treatment of a wide variety of indications including joint osteoarthritis, tendinopathies, woman health and dermo-aesthetics. The Company’s medical devices are also manufactured in the factory of Le Mont-sur-Lausanne (Switzerland) & New York (USA).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611846846/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 02:00:00 CET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn
Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 00:34:00 CET | Press release
Announcement of Enry’s Island AdVentures: the world’s first video game to learn how to launch and scale startups, focused on democratizing innovation for “Long Tail Users” Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of
500 Global Expands Africa Presence; Selected to Advance Digital Morocco 2030 Strategy18.12.2025 21:37:00 CET | Press release
Part of the Digital Morocco 2030 strategy, 500 Global has been selected to support the Startup Venture Building (Startup VB) initiative. 500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218363323/en/ Announcement of 500 Global's continued expansion across Africa and support of Digital Morocco 2030 Launched by the Ministry of Digital Transition and Administrative Reform (Ministry) and deployed by TAMWILCOM, the Startup VB initiative is a flagship program under the Digital Morocco 2030 strategy. Startup VB aims to streng
Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering18.12.2025 17:00:00 CET | Press release
New capital accelerates Neural Concept’s ability to deliver transformative technologies and enterprise-wide AI impact across advanced industrial workflows.Platform delivers CAD-native, physics-aware AI and deep reasoning for engineering, saving customers $50 million annually, reducing late-stage redesigns by 30-50% and accelerating time to market by up to two years.The company has generated a fourfold increase in enterprise revenue over the past 18 months.More than 50 global companies are actively relying on the platform, including General Motors, General Electric Vernova, Leonardo Aerospace, Eaton, Safran, Renault Group and multiple Formula 1 teams. Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press
Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF18.12.2025 16:57:00 CET | Press release
Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1 This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice. With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1 What makes Exprecell™ special?MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom